Eine Weltneuheit in der Neugeborenenpflege: Japan genehmigt die zu 100 % aus Muttermilch hergestellten Nahrungsergänzungsmittel von Prolacta Bioscience als verschreibungspflichtiges Medikament für gefährdete Säuglinge.

Prolacta Bioscience Japan

310-721-9444 

Referenzen  

Kusuda S, Bennett MV, Gould JB, et al. Comparative analysis of necrotizing enterocolitis in preterm infants born in Japan and born to mothers of Japanese ethnicity in California. Sci Rep. 2025;15:9943. doi:10.1038/s41598-025-92393-yIsayama T. The clinical management and outcomes of extremely preterm infants in Japan: past, present, and future. Transl Pediatr. 2019;8(3):199-211. doi:10.21037/tp.2019.07.10 Daten in den Akten; estimated number of premature infants fed Prolacta's products from January 2007 to May 2025. Ozturk G, Paviani B, Rai R, et al. Investigating milk fat globule structure, size, and functionality after thermal processing and homogenization of human milk. Foods. 2024;13(8):1242. doi:10.3390/foods13081242 Liang N, Koh J, Kim BJ, et al. Structural and functional changes of bioactive proteins in donor human milk treated by vat-pasteurization, retort sterilization, ultra-high-temperature sterilization, freeze-thawing and homogenization. Front Nutr. Online veröffentlicht am 15. September 2022. doi:10.3389/fnut.2022.926814 Meredith-Dennis L, Xu G, Goonatilleke E, Lebrilla CB, Underwood MA, Smilowitz JT. Composition and variation of macronutrients, immune proteins, and human milk oligosaccharides in human milk from nonprofit and commercial milk banks. J Hum Lact. 2018;34(1):120-129. doi:10.1177/0890334417710635 

Logo - https://mma.prnewswire.com/media/1361490/Prolacta_Bioscience_Logo.jpg

 

 

View original content:https://www.prnewswire.com/news-releases/eine-weltneuheit-in-der-neugeborenenpflege-japan-genehmigt-die-zu-100--aus-muttermilch-hergestellten-nahrungserganzungsmittel-von-prolacta-bioscience-als-verschreibungspflichtiges-medikament-fur-gefahrdete-sauglinge-302692948.html